The trial, sponsored by National Taiwan University Hospital, aimed to evaluate the effects of early intervention with nocturnal non-invasive ventilation (NIV) on patients with Amyotrophic Lateral Sclerosis (ALS). Given the increasing prevalence of ALS and the significant unmet need for effective respiratory management, successful outcomes from this trial could position NIV as a standard care intervention, potentially leading to market opportunities in respiratory devices and ALS management. The competitive landscape includes other respiratory support technologies, but the focus on early intervention in ALS may differentiate this approach. Diligence should consider the regulatory pathway for device approval and reimbursement strategies in various markets.